The overall proportion of S. pneumoniae isolates and vaccine serotypes in AOM were significantly reduced by community-wide use of PCV7 vaccine in our practice. The proportion of Gram-negative bacteria became 2-fold more frequent than S. pneumoniae in AOM in PCV7-vaccinated young children where PCV7 uptake was community-wide and supply was adequate.
We sought to determine the current level of resistance in Haemophilus influenzae and Streptococcus pneumoniae, the primary pathogens of pediatric conjunctivitis. Between January 1997 and March 1998, we prospectively cultured acute conjunctivitis in 250 ambulatory pediatric patients from rural Kentucky whose average age was 24.3 months. In those 250 cases, 106 H. influenzae (42% of the total) and 75 S. pneumoniae (30% of the total) pathogens were isolated, with no growth or no pathogen resulting in 79 cases (32% of the total). Beta-lactamase was detected in 60 (69%) of 87 tested strains of H. influenzae. Among 65 isolates of S. pneumoniae tested for penicillin susceptibility, 44 (68%) were susceptible, 17 (26%) were resistant, and 4 (6%) were intermediate. Conjunctivitis with acute otitis media was observed in 97 patients (39%), and H. influenzae was recovered in 57% of these 97 cases. As for in vitro activity, ciprofloxacin, ofloxacin, and tetracycline were the most active; and gentamicin, tobramycin, polymyxin B-trimethoprim, and polymyxin B-neomycin were intermediately active. Sulfamethoxazole possessed no activity against either pathogen. Beta-lactamase production was detected in 69% of H. influenzae strains, which still remains the primary causative pathogen of both conjunctivitis and conjunctivitis-otitis syndrome. Penicillin-nonsusceptible S. pneumoniae was observed in 32% of 65 patients with S. pneumoniae conjunctivitis, with most strains being penicillin resistant.Acute conjunctivitis is the most common ocular infection in childhood, usually affecting children younger than 6 years old with a peak incidence between 12 and 36 months (3). Pediatric acute conjunctivitis is diagnosed by clinical signs of ocular purulent discharge or hyperemia of bulbar conjunctiva. The etiology of this infection has been documented as bacterial in 54 to 73% of pediatric cases (3,20). The pathogens predominantly recovered include nontypeable Haemophilus influenzae (44 to 68% of cases) and Streptococcus pneumoniae (7 to 21% of cases). Concomitant infection with acute otitis media (AOM) has been coined the conjunctivitis-otitis syndrome by Bodor (4) and is associated with H. influenzae in 20 to 73% of cases and with S. pneumoniae in 12 to 20% of cases (4, 10). Other rare bacterial pathogens of conjunctivitis include Moraxella catarrhalis, Streptococcus mitis, and Streptococcus pyogenes (10,22).Clinicians nearly always empirically treat acute conjunctivitis with topical antimicrobial therapy. The disease is mild, cultures are rarely obtained because of expense, and culture results are reported days later (13). Compared with placebo, topical therapy with polymyxin-bacitracin ointment has been shown to reduce by half the duration of symptoms and to achieve a 2.5-fold increase in rate of bacteriologic eradication at days 8 to 10 (31 versus 79%, respectively) (6). Furthermore, selecting among the multitude of available topical antimicrobials to treat conjunctivitis has been based on either sparse in vitro data or on earlier limited c...
This is the first study to report the isolation of C. pneumoniae in middle ear fluid of children with AOM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.